AQUESTIVE THERAPEUTICS

Aquestive Therapeutics to Hold Virtual Investor Day to Provide Pipeline Updates on September 27th

09 Sep 2024 07:15:00 By Nasdaq GlobeNewswire

Aquestive Therapeutics to Participate in Two Upcoming Investor Conferences

22 Aug 2024 07:00:00 By Nasdaq GlobeNewswire

Aquestive Therapeutics Comments on Recent FDA Approval of Non-Injection-Based Epinephrine Product for the Treatment of Anaphylaxis and Reiterates Expected Timing for NDA Filing of Anaphylm™

14 Aug 2024 07:00:00 By Nasdaq GlobeNewswire

Aquestive Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update

06 Aug 2024 15:22:19 By Nasdaq GlobeNewswire

Aquestive Therapeutics Reports Positive Topline Data for Anaphylm™ (epinephrine) Sublingual Film from Self-Administration Study

25 Jul 2024 07:00:00 By Nasdaq GlobeNewswire

Aquestive Therapeutics to Report Second Quarter 2024 Financial Results and Recent Business Highlights on August 6 and Host Conference Call on August 7 at 8:00 a.m. ET

23 Jul 2024 07:00:01 By Nasdaq GlobeNewswire

Aquestive Therapeutics to Participate in Leerink Partners Therapeutics Forum: I&I and Metabolism

27 Jun 2024 07:00:00 By Nasdaq GlobeNewswire

Aquestive Therapeutics Reports Positive Topline Data from Temperature / pH Study of Anaphylm™ (epinephrine) Sublingual Film

25 Jun 2024 07:00:00 By Nasdaq GlobeNewswire

Aquestive Therapeutics to Join the Russell 3000® and Russell 2000® Indexes Effective June 28, 2024

18 Jun 2024 07:00:00 By Nasdaq GlobeNewswire

Aquestive Therapeutics Announces Executive Appointments and Builds Commercial Capabilities

03 Jun 2024 07:00:00 By Nasdaq GlobeNewswire

Aquestive Therapeutics to Present Anaphylm™ (epinephrine) Sublingual Film Pharmacokinetic and Pharmacodynamic Data At 2024 Eastern Allergy Conference

28 May 2024 07:00:00 By Nasdaq GlobeNewswire

Aquestive Therapeutics to Participate in The Citizens JMP Life Sciences Conference

09 May 2024 07:00:00 By Nasdaq GlobeNewswire

Aquestive Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update

07 May 2024 15:19:11 By Nasdaq GlobeNewswire

Aquestive Therapeutics Receives U.S. FDA Approval and Market Access for Libervant™ (diazepam) Buccal Film in Pediatric Patients Ages 2 to 5 and Provides Update on Anaphylm™ (epinephrine) Sublingual Film

29 Apr 2024 06:00:00 By Nasdaq GlobeNewswire

Aquestive Therapeutics to Report First Quarter 2024 Financial Results and Recent Business Highlights on May 7 and Host Conference Call on May 8 at 8:00 a.m. ET

25 Apr 2024 07:00:00 By Nasdaq GlobeNewswire

Aquestive Therapeutics to Present Crossover Study Data for Libervant™ (diazepam) Buccal Film at 76th Annual Meeting of the American Academy of Neurology

12 Apr 2024 15:01:00 By Nasdaq GlobeNewswire

Aquestive Therapeutics Strengthens Board of Directors with Experienced Biotech Executive

01 Apr 2024 07:00:00 By Nasdaq GlobeNewswire

Aquestive Therapeutics Announces Closing of Underwritten Public Offering of Common Stock

25 Mar 2024 07:00:25 By Nasdaq GlobeNewswire

Aquestive Therapeutics Announces Pricing of $75 Million Underwritten Public Offering of Common Stock

19 Mar 2024 20:49:43 By Nasdaq GlobeNewswire

Aquestive Therapeutics Announces Proposed Public Offering of Common Stock

19 Mar 2024 15:01:00 By Nasdaq GlobeNewswire